Atorvastatin might improve ventricular electrostability and decelerate the deterioration of renal function in patients with heart failure and diabetes mellitus

Journal of Cardiology

Volumn 53, Issue 3, 2009, Pages 341-348

  Kishi, Takuya ^a   Yamada, Akira ^b   Okamatsu, Shuuichi ^b   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ASO IIZUKA HOSPITAL   (Japan)

Author keywords

Atorvastatin; Diabetes mellitus; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE EXTRASYSTOLE; HOSPITAL READMISSION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY;

AGED; DIABETES MELLITUS; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HEART VENTRICLES; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PYRROLES; RETROSPECTIVE STUDIES; VENTRICULAR PREMATURE COMPLEXES;

EID: 67249087951     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2008.12.002     Document Type: Article

References (35)

1. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., and Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332 (1995) 481-487
2. Ferro D., Parrotto S., Basili S., Alessandri C., and Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 36 (2000) 427-431
3. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., Wen J., and Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
4. Oi S., Haneda T., Osaki J., Kashiwagi Y., Nakamura Y., Kawabe J., and Kikuchi K. Lovastatin prevents angiotensin-II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 376 (1999) 139-148
5. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
6. Dechend R., Fiebeler A., Park J.K., Muller D.N., Theuer J., Mervaala E., Bieringer M., Gulba D., Dietz R., Luft F.C., and Haller H. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 104 (2001) 576-581
7. Vaughan C.J., Murphy M.B., and Buckley B.M. Statins do more than just lower cholesterol. Lancet 348 (1996) 1079-1082
8. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
9. Yamada T., Node K., Mine T., Morita T., Kioka H., Tsukamoto Y., Tamaki S., Masuda M., Okuda K., and Fukunami M. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 153 (2007) 1055.e1-e8
10. Krum H., and McMurray J.J. Statins and chronic heart failure: do we need a large-scale outcome trial?. J Am Coll Cardiol 39 (2002) 1567-1573
11. Horwich T.B., Hamilton M.A., Maclellan W.R., and Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 (2002) 216-224
12. Khush K.K., Waters D.D., Bittner V., Deedwania P.C., Kastelein J.J.P., Lewis S.J., and Wenger N.K. Effect of high-dose atorvastatin on hospitalization for heart failure. Circulation 115 (2007) 576-583
13. Kadota S., Matsuda M., Izuhara M., Baba O., Morikawa S., Shioji K., Takeuchi Y., and Uegaito T. Long-term effects of early statin therapy for patients with acute myocardial infarction treated with stent implantation. J Cardiol 51 (2008) 171-178
14. Cleland J.G., Swedberg K., Follath F., Komajda M., Cohen-Solal A., Aguilar J.C., Dietz R., Gavazzi A., Hobbs R., Korewicki J., Madeira H.C., Moiseyev V.S., Preda I., van Gilst W.H., Widimsky J., et al. Study group on diagnosis of the working group on heart failure of the European society of cardiology: the Euroheart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Eur Heart J 24 (2003) 442-463
15. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland L., Schumacher H., Dagenais G., Sleight P., and Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
16. Sassa S., Shimada K., Yoshida K., Tanaka H., Jissho S., and Yoshikawa J. Comparison of 64-slice multi-detector computed tomography coronary angiography between asymptomatic, type 2 diabetes mellitus and impaired glucose tolerance patients. J Cardiol 52 (2008) 133-139
17. Eriksson H., Svardsudd K., Larsson B., Ohlson L.O., Tibblin G., Welin L., and Wilhelmsen L. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J 10 (1989) 647-656
18. Imai E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T., Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11 (2007) 41-50
19. Lown B., and Wolf M. Approaches to sudden death from coronary heart disease. Circulation 44 (1971) 130-142
20. Trochu J.N., Mital S., Zhang X., Xu X., Ochoa M., Liao J.K., Recchia F.A., and Hintze T.H. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res 60 (2003) 250-258
21. Mozaffarian D., Mina mi E., Letterer R., Lawler R.L., McDonald G.B., and Levy W.C. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 96 (2005) 1699-1704
22. Sola S., Mir M.Q., Lerakis D., Tandon N., and Khan B.V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
23. Pliquett R.U., Cornish K.G., and Zucker I.H. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 95 (2003) 700-704
24. Wojnicz R., Wilczek K., Nowalany-Kozielska E., Szygula-Jurkiewicz B., Nowak J., Polonski L., Dyrbuś K., Badziński A., Mercik G., Zembala M., Wodniecki J., and Rozek M.M. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 97 (2006) 899-904
25. Mallat Z., Philip L., Lebret M., Chatel D., Maclouf J., and Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilation and progression to heart failure. Circulation 97 (1998) 1536-1539
26. Dhalla A.K., Hill M.F., and Singal P.K. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 28 (1996) 506-514
27. Li J.M., Gall N.P., Grieve D.J., Chen M., and Shah A.M. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40 (2002) 477-484
28. Maack C., Kartes T., Kilter H., Schafers H.J., Nickenig G., Bohm M., and Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108 (2003) 1567-1574
29. Tsutsui T., Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Ohnishi M., and Kinoshita M. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 39 (2002) 957-962
30. Boudina S., and Abel E.D. Diabetic cardiomyopathy revisited. Circulation 115 (2007) 3213-3223
31. Pinsky D.J., Cai B., Yang X., Rodriguez C., Sciacca R.R., and Cannon P.J. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthetase antagonism or transforming growth factor beta. J Clin Invest 95 (1995) 677-685
32. Kishi T., Hirooka Y., Shimokawa H., Takeshita A., and Sunagawa K. Atorvastatin reduced oxidative stress in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 30 (2008) 3-11
33. Kishi T., Hirooka Y., Kimura Y., Ito K., Shimokawa H., and Takeshita A. Increased reactive oxygen species in rostral ventrolateral medulla to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 109 (2004) 2357-2362
34. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
35. Campese V.M., and Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int 71 (2007) 1215-1222